Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Gliosarcoma 4Glioblastoma 4Sarcoma, Ewing 2Oligodendroglioma 2Glioma, Subependymal 2Glioma 2Ependymoma 2Astrocytoma 2Rhabdomyosarcoma 1Pinealoma 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

Specimen Handling 9Paclitaxel 7Magnetic Resonance Spectroscopy 6Carboplatin 6Biopsy 6Nivolumab 5pembrolizumab 3olaparib 3X-Rays 3durvalumab 2ceralasertib 2cediranib 2Taxes 2Immunoglobulin G 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pazopanib 1pamiparib 1liposomal doxorubicin 1cobimetinib 1capivasertib 1cabozantinib 1belinostat 1atezolizumab 1apatinib 1Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × Congresses as Topic × Sarcoma × Clear all
NCT04214067 2026-05-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
164 enrolled
Sarcoma

Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡